The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kinkulkina M.A.

Sechenov First Moscow State Medical University (Sechenov University)

Volel’ B.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Smolyarchuk E.A.

Sechenov First Moscow Medical University

Morozov E.N.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ivaschenko A.V.

ChemDiv Inc.

Ivaschenko A.A.

Lomonosov Moscow State University

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

Zilov V.G.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Tikhonova Yu.G.

Sechenov First Moscow State Medical University (Sechenov University)

Izyumina T.A.

Sechenov First Moscow State Medical University (Sechenov University)

Belyaeva P.A.

Psychotherapy Center «Podderzhka»

Izmailova O.V.

Samara State Medical University

Mavani D.Ch.

LLC Medical Center «Nova Vita»

Penchul N.A.

State Public Health Institution «Leningrad Regional Mental Health Center»

Balaban I.V.

LLC «Avrora MedFort»

Gylypkylova K.K.

«Eco-Safety» R and D Center

Moskovtseva O.R.

State Public Health Institution «Psychoneurological dispensary No. 5»

Golovkina D.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Goncharova E.M.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Gorchakov D.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Morozov A.E.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Tarasov V.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Efficacy and safety of AVIANDR in the treatment of panic disorder: results of the first stage of the multicenter, randomized, placebo-controlled study

Authors:

Kinkulkina M.A., Volel’ B.A., Smolyarchuk E.A., Morozov E.N., Ivaschenko A.V., Ivaschenko A.A., Ivanets N.N., Zilov V.G., Tikhonova Yu.G., Izyumina T.A., Belyaeva P.A., Izmailova O.V., Mavani D.Ch., Penchul N.A., Balaban I.V., Gylypkylova K.K., Moskovtseva O.R., Golovkina D.A., Goncharova E.M., Gorchakov D.S., Morozov A.E., Tarasov V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12): 161‑171

DOI: 10.17116/jnevro2025125121161

Read: 1230 times

Buy for 300₽
Contact the author
Table of contents

EFFICACY AND SAFETY OF AVIANDR IN THE TREATMENT OF PANIC DISORDER: RESULTS OF THE FIRST STAGE OF THE MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY
EFFICACY AND SAFETY OF AVIANDR IN THE TREATMENT OF PANIC DISORDER: RESULTS OF THE FIRST STAGE OF THE MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY

To cite this article:

Kinkulkina MA, Volel’ BA, Smolyarchuk EA, et al. Efficacy and safety of AVIANDR in the treatment of panic disorder: results of the first stage of the multicenter, randomized, placebo-controlled study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12):161‑171. (In Russ.)
https://doi.org/10.17116/jnevro2025125121161

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107
Inve­stigation of the rela­tionship of indi­vidual characteristics of the brain bioelectrical acti­vity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117
Psycho-emotional state and self-reported sleep quality in students with bimo­dality of the ability to be active in the morning and evening in the sleep—wake cycle. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):130-134
Effe­cts of sema­glutide on mental health. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):28-36
Basic and complex therapy of non-segmental viti­ligo with como­rbid anxiety and anxiety-depressive adju­stment diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):51-58
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Conscious seda­tion with benzodiazepines in pediatric outpatient dentistry. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):55-63
Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37
Community-acquired pneumonia in adults. Clinical guidelines 2024 (short version). Journal of Respiratory Medi­cine. 2025;(3):6-18
Abstract:

OBJECTIVE

To evaluate the efficacy and safety of non-benzodiazepine anxiolytic maritupirdine (Aviandr) in patients with panic disorder.

MATERIAL AND METHODS

In a multicenter, randomized, double-blind, placebo-controlled study with an open-label comparison, 288 patients with moderate PD were assigned to receive Aviandr 40 mg/day (n=144), placebo (n=72), or paroxetine 40 mg/day (n=72). The treatment duration was 12 weeks. Clinical and psychopathological, psychometric methods and statistical analysis were used. The Panic Disorder Severity Scale (PDSS), the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), the Clinical Global Impression Scale (CGI), the Visual Analog Scale (VAS) of daytime sleepiness and the Sheehan Disability Scale (SDS) were used for a standardized assessment of the state change. The primary endpoint was the change in Panic Disorder Severity Scale (PDSS) total score at week 12.

RESULTS

The PDSS score reduction in the Aviandr group (–4.99) was statistically and clinically significantly greater than in the placebo group (–2.28; p=0.047). The drug demonstrated a rapid onset of action, with significant improvement beginning at week 2. Aviandr’s efficacy on secondary endpoints (SIGH-A and CGI) was also superior to placebo. The need for symptomatic hydroxyzine therapy was significantly lower in the Aviandr group. The safety profile was favorable, with adverse event rates comparable to placebo (44.44%) and lower than in the paroxetine group (50%). No serious adverse events were recorded.

CONCLUSION

Aviandr demonstrated statistically significant superiority over placebo, rapid onset of action, and a favorable safety profile, making it a promising treatment option for panic disorder.

Keywords:

panic disorder
anxiety
panic attack
therapy
SSRI
paroxetine
Aviandr

Authors:

Kinkulkina M.A.

Sechenov First Moscow State Medical University (Sechenov University)

Volel’ B.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Smolyarchuk E.A.

Sechenov First Moscow Medical University

Morozov E.N.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ivaschenko A.V.

ChemDiv Inc.

Ivaschenko A.A.

Lomonosov Moscow State University

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

Zilov V.G.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Tikhonova Yu.G.

Sechenov First Moscow State Medical University (Sechenov University)

Izyumina T.A.

Sechenov First Moscow State Medical University (Sechenov University)

Belyaeva P.A.

Psychotherapy Center «Podderzhka»

Izmailova O.V.

Samara State Medical University

Mavani D.Ch.

LLC Medical Center «Nova Vita»

Penchul N.A.

State Public Health Institution «Leningrad Regional Mental Health Center»

Balaban I.V.

LLC «Avrora MedFort»

Gylypkylova K.K.

«Eco-Safety» R and D Center

Moskovtseva O.R.

State Public Health Institution «Psychoneurological dispensary No. 5»

Golovkina D.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Goncharova E.M.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Gorchakov D.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Morozov A.E.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Tarasov V.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Received:

26.11.2025

Accepted:

08.12.2025

Close metadata

References:

  1. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues in clinical neuroscience. 2015;17(3):327-335.  https://doi.org/10.31887/DCNS.2015.17.3/bbandelow
  2. de Jonge P, Roest AM, Lim CC, et al. Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depression and anxiety. 2016;33(12):1155-1177. https://doi.org/10.1002/da.22572
  3. Psychiatry. National Guidelines. Edited by Yu.A. Aleksandrovsky, N.G. Neznanov. 2nd ed., revised and enlarged. M.: GEOTAR-Media; 2018. (In Russ.).
  4. Schenberg LC. Panic disorder. Neuroscience and Biobehavioral Reviews. 2014;46(3):343-344.  https://doi.org/10.1016/j.neubiorev.2014.11.004
  5. Chen YH, Hu CJ, Lee HC, et al. An increased risk of stroke among panic disorder patients: a 3-year follow-up study. Canadian Journal of Psychiatry. 2010;55(1):43-49. 
  6. Goodwin RD, Wamboldt FS. Childhood physical abuse and respiratory disease in the community: the role of mental health and cigarette smoking. Nicotine & Tobacco Research. 2012;14(1):91-97.  https://doi.org/10.1093/ntr/ntr126
  7. Kim YK. Panic Disorder: Current Research and Management Approaches. Psychiatry Investigation. 2019;16(1):1-3.  https://doi.org/10.30773/pi.2019.01.08
  8. Harber L, Hamidian R, Bani-Fatemi A, et al. Meta-Analysis of Neuropsychological Studies in Panic Disorder Patients: Evidence of Impaired Performance during the Emotional Stroop Task. Neuropsychobiology. 2019;78(1):7-13.  https://doi.org/10.1159/000496623
  9. Beşirli A. The relationship between impulsivity and panic disorder-agoraphobia: the role of affective temperament. Psychiatry Research. 2018;264:169-174.  https://doi.org/10.1016/j.psychres.2018.03.021
  10. Lawrence PJ, Murayama K, Creswell C. Systematic Review and Meta-Analysis: Anxiety and Depressive Disorders in Offspring of Parents With Anxiety Disorders. Journal of the American Academy of Child & Adolescent Psychiatry. 2019;58(1):46-60.  https://doi.org/10.1016/j.jaac.2018.07.898
  11. Koskinen MK, Hovatta I. Genetic insights into the neurobiology of anxiety. Trends in Neurosciences. 2023;46(4):318-331.  https://doi.org/10.1016/j.tins.2023.01.007
  12. Goddard AW. The Neurobiology of Panic: A Chronic Stress Disorder. Chronic Stress. 2017;1:2470547017736038. https://doi.org/10.1177/2470547017736038
  13. Panicheskoe rasstrojstvo: Klinicheskie rekomendacii. Moscow: Ministerstvo zdravookhraneniya Rossijskoj Federacii. 2024. Accessed 14.11.2025. (In Russ.). https://cr.minzdrav.gov.ru/view-cr/456_3
  14. Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews. 2019;3(3):CD010677. https://doi.org/10.1002/14651858.CD010677.pub2
  15. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;376:e066084. https://doi.org/10.1136/bmj-2021-066084
  16. Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews. 2023;11(11):CD012729. https://doi.org/10.1002/14651858.CD012729.pub3
  17. Cartwright C, Gibson K, Read J, et al. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Preference and Adherence. 2016;10:1401-1407. https://doi.org/10.2147/PPA.S110632
  18. Ivashchenko AA, Morozova MA, Vostokova NV, et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study. Journal of Psychiatric Research. 2021;143:436-444.  https://doi.org/10.1016/j.jpsychires.2021.10.008
  19. Morozova MA, Safarova TP, Gluskina LYa, et al. Double-blind, placebo-controlled study of the efficacy and tolerability of Aviander® in the treatment of generalized anxiety disorder. Modern Therapy of Mental Disorders. 2024;3:2-16. (In Russ.).
  20. Popova VB, Antonova EA, Khlyabova PM, et al. Efficacy and safety of Aviandr in the treatment of anxiety in patients with adjustment disorders after COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7):131-138. (In Russ.). https://doi.org/10.17116/jnevro2024124071131
  21. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative Panic Disorder Severity Scale. American Journal of Psychiatry. 1997;154(11):1571-1575. https://doi.org/10.1176/ajp.154.11.1571
  22. Shea MK, Vander Bilt J, Rucci P, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depression and Anxiety. 2001;13:166.178.  https://doi.org/10.1002/da.1033
  23. Kinkulkina MA, Danilov AB, Volel BA, et al. Efficacy and safety of Aviandr® in patients with anxiety disorders after coronavirus infection (COVID-19): interim results of a multicenter observational post-registration study. Bulletin of Neurology, Psychiatry and Neurosurgery. 2025;1. (In Russ.). https://doi.org/10.33920/med-01-2501-10
  24. Haddad M, Dieckmann LHJ, Viola TW, et al. The Efficacy of Fluvoxamine in Anxiety Disorders and Obsessive-Compulsive Disorder: An Overview of Systematic Reviews and Meta-Analyses. Pharmaceuticals. 2025;18(3):353.  https://doi.org/10.3390/ph18030353
  25. Zhang B, Wang C, Cui L, et al. Short-Term Efficacy and Tolerability of Paroxetine Versus Placebo for Panic Disorder: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology. 2020;11:275.  https://doi.org/10.3389/fphar.2020.00275
  26. Hobgood CD, Clayton AH. Sertraline in the treatment of panic disorder. Drugs of Today. 2009;45(5):351-361.  https://doi.org/10.1358/dot.2009.45.5.1362066
  27. Blumenthal JA, Smith PJ, Jiang W, et al. Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients with Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients with Coronary Heart Disease (UNWIND) Randomized Clinical Trial. JAMA psychiatry. 2021;78(11):1270-1278. https://doi.org/10.1001/jamapsychiatry.2021.2236
  28. Katzman MA, Jacobs L. Venlafaxine in the treatment of panic disorder. Neuropsychiatric Disease and Treatment. 2007;3(1):59-67.  https://doi.org/10.2147/nedt.2007.3.1.59
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.